Freienbach, May 7^th 2024 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced that it has signed License and Distribution Agreement exclusively for Binosto^® in Indonesia with Pyridam Farma (PT Pyridam Farma Tbk), a leading public listed pharmaceutical company in Indonesia.

Binosto^® (buffered soluble alendronate) is indicated for the treatment of postmenopausal osteoporosis and is currently marketed in Europe, US, Middle East, and Asia. It offers an important treatment option for postmenopausal women suffering from osteoporosis, effectively reducing the risk of debilitating fractures. Binosto^® is associated with a lower frequency of upper gastrointestinal side effects and demonstrates higher persistence compared to reported cases with alendronate tablets.

Dr. Widjanarko Brotosaputro, Director of Pyridam Farma said, “We are thrilled to collaborate with EffRx Pharmaceuticals and eagerly anticipate the positive impact it will have on Indonesia healthcare accessibility. We believe this collaboration has the potential to significantly enhance healthcare access to osteoporosis patients and to deliver an innovative solution to our national healthcare system. Together we are committed to driving positive change and improving the health of Indonesian patients.”

Lorenzo Bosisio, CEO of EffRx, said, “We are delighted to announce the partnership with Pyridam Farma to further expand the footprint of Binosto^®. Pyridam Farma is a recognized, dynamic healthcare company well-rooted in the Indonesian market, hence representing the partner of choice for our firm.  Pyridam’s commitment to patients living a healthier life embraces Binosto^® promise to alleviate the burden of osteoporosis of Indonesian women suffering from this debilitating bone-thinning disease.”

Under the terms of the agreement, EffRx will grant Pyridam Farma an exclusive license to commercialize Binosto^® in Indonesia and will also supply the product. 

About BINOSTO^®:

Binosto^® (alendronate 70 mg effervescent tablets) is the first and only buffered solution for the treatment of postmenopausal osteoporosis and bone to increase bone mass in men. It reduces the risk of hip, spine, and non-spine fractures. Binosto^® is taken once a week as an easy-to-swallow, buffered solution with no risk of a tablet getting lodged in the esophagus. The buffered solution with high acid-neutralizing capacity minimizes the risk of exposing the esophagus (in case of reflux) and the stomach to acidified alendronate.^1,2 Binosto^® is associated with a lower frequency of upper GI side effects than reported for alendronate tablets³ and with higher persistence than alendronate tablets^4,5, thereby decreasing the risk of disabling fractures.

Disclaimer:  Please refer to the official Binosto^® prescribing information and approved indications, contraindications, and warnings in your country.

About EffRx Pharmaceuticals:

EffRx Pharmaceuticals SA is a Swiss commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications. EffRx’s lead commercialized product, Binosto^® for the treatment of osteoporosis, is successfully commercialized by Licensees across European, Asian and Middle Eastern countries. EffRx is controlled by Abiogen Pharma S.p.A., an Italian leading company in the field of osteoarticular and bone metabolism diseases.

About Pyridam Farma:

PT Pyridam Farma Tbk is a pharmaceutical company with the main business being the production and commercialization of modern and traditional medicines as well as the distribution of medical devices such as laboratory equipment and PCR test kits. This company was founded in 1976 and has been a public company and listed on the Indonesia Stock Exchange since 2001.PT Pyridam Farma Tbk produces various kinds of pharmaceutical products ranging from antibiotics, vitamins, health supplements, to traditional medicines.

 References:

1. Binosto EU Summary of Product Characteristics 2023.
2. Hodges LA et al. Modulation of gastric pH by a buffered soluble effervescent formulation: a possible means of improving gastric tolerability of alendronate. Int J Pharm 2012.
3. Minisola S et al. A Prospective Open‐Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study. JBMR Plus 2021.
4. Giusti A et al. A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis. Aging Clin Exp Res 2021.
5. Gonnelli S et al. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study. Aging Clin Exp Res 2019.
   
   

Contact:

Pyridam Farma

Kezia Mareshah

Corporate Communication Manager Pyridam Farma

corcomm@pyfa.co.id

EffRx Pharmaceuticals

info@effrx.com